CRC Trial

CRC clinical investigators are participating in the listed clinical trials. Site participation varies. In order to find out more about the clinical trials occurring at the CRC site nearest you, please contact a research site from the Quick Links section. The research nurses/coordinators will be able to assist you with the details of these clinical trials and others being conducted at each local site. What is a Clinical Trial?

Protocols

CRC014 Revlimid® and Rituximab: A Two-Arm, Multi-center trial of Revlimid® and Rituximab, for First-Line Treatment in Patients with B-cell Chronic Lymphocytic Leukemia (CLL) Brief Description: The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consoritum (CRC).

The purpose of this study is to determine the response rate of the combination of Revlimid® and Rituximab in previously untreated CLL patients in two arms- those aged 65 years and above and those younger than 65. Secondary objectives will evaluate the safety of the combination of Revlimid® and Rituximab, response duration, improvement in hematologic parameters, and the prognostic role of the tumor flare reaction.

All patients will have assessment of known prognostic factors for CLL as well as novel prognostic factors will be evaluated for predicting response to treatment. Biologic corollary studies are designed to evaluate the mechanism of Revlimid® in CLL and the combination of Revlimid® and Rituximab. To read more about this important study click the following link: CRC014 Abstract

CRC012 OFAR II:Phase I/II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients with Richter's Transformation, Prolymphocytic Leukimia or Refractory /Relpsed B-Cell Chronic Lymphocytic Leukemia. Click here for crc012 Abstract

CRC000 CLL Research Consortium Tissue Core Sample Collection Study and Familial: This Study Sample Collection. The CRC tissue core study is one of the world's, if not the worlds, largest repositories of CLL materials. The collection of samples from patients around the world enable researchers to uncover CLL's mechanisms of action, with the hopeful result of developing curative stategies for patient with CLL. Click Here for the CRC000 Tissue Core Abstract

CRC011 Heavy Water:This is a Kinetic Biomarker for study for Chronic Lymphocytic Leukemia (CLL). The fundamental disorder in cancer is altered cell kinetics (cell proliferation and/or death). The ideal biomarker for cancer would therefore measure these cellular kinetic events directly. CLL is an excellent clinical cancer model for applying a kinetic biomarker, by virtue of its accessibility (being a liquid tumor) and its relatively well-established kinetic basis. The laboratory of Dr. Marc Hellerstein at the University of California, Berkeley has developed, patented, and extensively used a direct kinetic biomarker of cell proliferation and death in humans. The technique is based on stable (non-radioactive) isotope incorporation (e.g. heavy water) into cellular DNA followed by mass spectrometric analysis and is exclusively licensed to KineMed, Inc. - a company formed to commercialize kinetic measurements in medical diagnostics and drug development.
Preliminary data suggests this is a safe and non-toxic method for accurately measuring cell proliferation and turnover in vivo in B-CLL may prove to be of significant prognostic utility in patients with early stage disease. After heavy water (deuterated water, 2H2O) is orally administered, deuterium (2H) is incorporated into the deoxyribose (dR) moiety of purine deoxyribonucleotides in DNA of dividing cells. Blood or bone marrow is obtained at appropriate time points. DNA is isolated, and the amount of 2H incorporated into DNA is quantified by mass spectrometry, allowing for a measure of cellular proliferation. There is no radioactivity involved, and there are no known risks of heavy water at the doses that we administer. Click here for the Heavy Water Abstract

The Latest Clinical Trials at CRC Sites: